Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

Open access

Published version of a preprint

Abstract

Abstract Purpose: Urelumab is an agonist antibody to CD137 with potential application as an immuno-oncology therapeutic. Data were analyzed to assess safety, tolerability, and pharmacodynamic activity of urelumab, including the dose selected for ongoing development in patients with advanced solid tumors and lymphoma. Experimental Design: A total of 346 patients with advanced cancers who had progressed after standard treatment received at least one dose of urelumab in one of three dose–escalation, monotherapy studies. Urelumab was administered at doses ranging from 0.1 to 15 mg/kg. Safety analyses included treatment-related and serious adverse events (AEs), as well as treatment-related AEs leading to discontinuation and death, with a focus on liver function test abnormalities and hepatic AEs. Results: Urelumab doses between 1 and 15 mg/kg given every 3 weeks resulted in a higher frequency of treatment-related AEs than 0.1 or 0.3 mg/kg every 3 weeks. Dose was the single most important factor contributing to transaminitis development, which was more frequent and severe at doses ≥1 mg/kg. At the MTD of 0.1 mg/kg every 3 weeks, urelumab was relatively well tolerated, with fatigue (16%) and nausea (13%) being the most common treatment-related AEs, and was associated with immunologic and pharmacodynamic activity demonstrated by the induction of IFN-inducible genes and cytokines. Conclusions: Integrated evaluation of urelumab safety data showed significant transaminitis was strongly associated with doses of ≥1 mg/kg. However, urelumab 0.1 mg/kg every 3 weeks was demonstrated to be safe, with pharmacodynamic activity supporting continued clinical evaluation of this dose as monotherapy and in combination with other immuno-oncology agents. Clin Cancer Res; 23(8); 1929–36. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-16-1272

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Show all 24 references

Research works printed but not linked: 1

  1. Jure-Kunkel, 2006, Functional characterization of fully human anti-CD137 antibodies

Cited by

See all 424

Metadata

Authors
Segal, N. H., Logan, T. F., Hodi, F. S., McDermott, D., Melero, I., Hamid, O., Schmidt, H., Robert, C., Chiarion-Sileni, V., Ascierto, P. A., Maio, M., Urba, W. J., Gangadhar, T. C., Suryawanshi, S., Neely, J., Jure-Kunkel, M., Krishnan, S., Kohrt, H., Sznol, M., & Levy, R.
Affiliations
  • Memorial Sloan Kettering Cancer Center (US)
  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center (US)
  • Dana-Farber Cancer Institute (US)
  • Beth Israel Deaconess Medical Center (US)
  • Clinica Universidad de Navarra (ES)
  • Angeles Clinic and Research Institute (US)
  • Aarhus University Hospital (DK)
  • Institut Gustave Roussy (FR)
  • 9Istituto Oncologico Veneto, Padua, Italy.
  • Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
  • University of Siena (IT)
  • Providence Portland Medical Center (US)
  • Abramson Cancer Center (US)
  • Bristol-Myers Squibb (United States) (US)
  • 14Bristol-Myers Squibb, Princeton, New Jersey.
  • Stanford Medicine (US)
  • Yale Cancer Center (US)
Corresponding author
Levy, Ronald
Venue
Clinical Cancer Research
Published
2017-04-13
Volume
23
Issue
8
Pages
1929-1936
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2537734913
Cited by
424
References
24
Citations by year
2026: 35 · 2025: 40 · 2024: 41 · 2023: 60 · 2022: 48 · 2021: 64 · 2020: 45 · 2019: 37 · 2018: 31 · 2017: 20
FWCI
15.98
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • Use Siena air (University of Siena) (submittedVersion)
  • IUScholarWorks (Indiana University) (submittedVersion)
Funders
Bristol-Myers Squibb
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
urelumab, anti-CD137 monoclonal antibody, dose escalation, maximum tolerated dose, elevated liver enzymes, hepatotoxicity, liver function tests, treatment-related adverse events, fatigue, nausea, cytokines, immunotherapy, advanced solid tumors, lymphoma
MeSH terms
Adult, Aged, Antibodies, Monoclonal, Antineoplastic Agents, Dose-Response Relationship, Drug, Female, Humans, Male, Melanoma, Middle Aged, Neoplasms, Maximum Tolerated Dose, 4-1BB Ligand

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-1272
The paper
Segal, N. H., Logan, T. F., Hodi, F. S., McDermott, D., Melero, I., Hamid, O., Schmidt, H., Robert, C., Chiarion-Sileni, V., Ascierto, P. A., Maio, M., Urba, W. J., Gangadhar, T. C., Suryawanshi, S., Neely, J., Jure-Kunkel, M., Krishnan, S., Kohrt, H., Sznol, M., & Levy, R. (2017). Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-1272

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.